ArticleDiscover oncology2026
LightGBM-guided discovery of mechanistic biomarkers in thyroid cancer: GALNT7 and SKP1P1 emerge as therapeutic targets.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Thyroid carcinoma (THCA) exhibits molecular heterogeneity, necessitating robust biomarkers for precise diagnosis and mechanistic insights. In this study, we integrated the transcriptomic data of THCA and normal thyroid tissues from The Cancer Genome Atlas and Genotype-Tissue Expression (GTEx) databases using ComBat-based batch correction, identifying 5,573 differentially expressed genes. Functional enrichment showed that these genes were associated with dysregulation in immune-microenvironment interactions and post-transcriptional regulatory pathways. After a comparison of seven machine-learning algorithms, LightGBM was selected for its high discrimination performance and interpretability. Using this algorithm, we obtained an 8-gene diagnostic panel comprising a glycosyltransferase (GALNT7), pseudogenes (HIRAP1, SKP1P1), miRNAs (MIR331, MIR93), and novel transcripts. siRNA-mediated knockdown of GALNT7 and SKP1P1 significantly attenuated the proliferative and migratory abilities and clonogenicity of the THCA cell line TPC-1 in vitro. Immune correlation analysis revealed the tumor-specific suppression of stromal components by GALNT7 and normal tissue-specific lymphoid regulation by SKP1P1, suggesting the different roles of these components in microenvironment remodeling. Knockdown of HIRAP1, MIR331, and MIR93 had no statistically significant effects on these oncogenic phenotypes. However, their high predictive value in the computational model suggests they may serve as effective biomarkers for tumor classification, independent of their functional roles in tumorigenesis. These findings highlight the importance of orthogonal experimental validation in linking computational biomarker discovery with biological causality. This study suggests that GALNT7 and SKP1P1 are promising diagnostic biomarkers and therapeutic targets for THCA, with dual roles in tumor-specific signaling and immune microenvironment modulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.